Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Purine analogues

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44363   clinical trials with a EudraCT protocol, of which   7387   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    9 result(s) found for: Purine analogues. Displaying page 1 of 1.
    EudraCT Number: 2014-003046-27 Sponsor Protocol Number: HCL-PG03 Start Date*: 2014-09-27
    Sponsor Name:Dipartimento di Medicina
    Full Title: A PHASE II OPEN-LABEL SINGLE-CENTER STUDY OF THE CLINICAL ACTIVITY AND SAFETY OF THE BRAF-V600 INHIBITOR VEMURAFENIB (ZELBORAF) IN COMBINATION WITH THE B-CELL TARGETING ANTIBODY RITUXIMAB (MABTHERA...
    Medical condition: HAIRY CELL LEUKEMIA (HCL) CARRYING THE BRAF-V600E MUTATION
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-001669-27 Sponsor Protocol Number: CLLX2 Start Date*: 2011-06-28
    Sponsor Name:Universitätsklinikum Heidelberg
    Full Title: A phase-III study on the value of allogeneic stem cell transplantation in poor-risk chronic lymphocytic leukemia by the German CLL Study Group (GCLLSG) and the German Cooperative Transplant Study G...
    Medical condition: High-risk and very high-risk chronic lymphocytic leukemia (CLL)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008962 Chronic lymphocytic leukaemia refractory PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-005487-13 Sponsor Protocol Number: HCL-PG01 Start Date*: 2012-05-11
    Sponsor Name:UNIVERSITA' DEGLI STUDI DI PERUGIA
    Full Title: A phase II, multi-center, open label study of the clinical activity and safety of the BRAF-V600 inhibitor vemurafenib (PLX-4032) in previously treated patients with hairy cell leukemia (HCL) carry...
    Medical condition: Hairy cell leukemia (HCL)carrying the BRAF-V600 mutation
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10019053 Hairy cell leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-001833-29 Sponsor Protocol Number: 202152 Start Date*: 2016-09-07
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A multicentre, randomised, double-blind (sponsor-unblinded), placebo-controlled study with open label extension to investigate the safety and tolerability, pharmacokinetics, pharmacodynamics, and...
    Medical condition: Active ulcerative colitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10017969 Gastrointestinal inflammatory conditions HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) GB (Completed) PL (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2010-023022-20 Sponsor Protocol Number: CLL2S Start Date*: 2011-08-03
    Sponsor Name:Universitätsklinikum Ulm
    Full Title: A Phase I/II, Multi-centre Trial to Assess the Safety, Efficacy, and Pharmacokinetics of Eltrombopag, Administered to Thrombocytopenic Chronic Lymphocytic Leukemia Patients Prior to Alkylating Agen...
    Medical condition: CLL patients with thrombocytopenia and indication for chemotherapeutic treatment with alkylating agents and/or purine analogues
    Disease: Version SOC Term Classification Code Term Level
    15.1 100000004864 10008977 Chronic lymphocytic leukemia recurrent LLT
    15.1 100000004864 10068919 B-cell chronic lymphocytic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) AT (Completed)
    Trial results: View results
    EudraCT Number: 2006-004218-42 Sponsor Protocol Number: P060207 Start Date*: 2008-01-30
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: Essai thérapeutique de phase IIA évaluant l'efficacité du Bortezomib (velcade) chez les patients atteints de la maladie de Waldenstrom en phase avancée
    Medical condition: Maladie de Waldenstrom réfractaire ou en rechute après une ou deux lignes de traitement ayant comporté des alkylants et/ou des analogues de purine et/ou un anticorps monoclonal seul ou en association.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10054695 Macroglobulinémie de Waldenström PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-005966-39 Sponsor Protocol Number: TJT1123 Start Date*: 2012-03-08
    Sponsor Name:CHU-ULg
    Full Title: Mesenchymal stem cell therapy for the treatment of severe or refractory inflammatory and/or autoimmune disorders.
    Medical condition: Crohn's disease
    Disease: Version SOC Term Classification Code Term Level
    14.0 10017947 - Gastrointestinal disorders 10011402 Crohn's disease (colon) LLT
    14.0 10021428 - Immune system disorders 10003816 Autoimmune disorders HLGT
    14.0 10017947 - Gastrointestinal disorders 10064147 Gastrointestinal inflammation PT
    14.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-003169-19 Sponsor Protocol Number: CYC-201 Start Date*: 2009-11-09
    Sponsor Name:Sigmoid Pharma Ltd
    Full Title: A Randomized, Double-blind, Placebo-controlled Study of a Controlled Release Minicapusle Formulation of Ciclosporin (CyCol™) in the Treatment of Ulcerative Colitis
    Medical condition: Ulcerative colitis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-001225-33 Sponsor Protocol Number: UC-0105/1401 Start Date*: 2014-07-21
    Sponsor Name:UNICANCER
    Full Title: Secured access to vemurafenib for patients with tumors harboring BRAF genomic alterations.
    Medical condition: Patient with BRAF V600 mutation determined on the primary and/or metastatic lesion in the following pathologies: . NSCLC . Ovarian cancer . Cholangiocarcinoma . Thyroid cancer . Prostatic canc...
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10019053 Hairy cell leukaemia PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10039491 Sarcoma PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005003 Bladder cancer PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008593 Cholangiocarcinoma PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008958 Chronic lymphocytic leukaemia PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071653 Gastrointestinal stromal cancer PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066474 Thyroid cancer PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10035226 Plasma cell myeloma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Nov 06 02:03:54 CET 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA